MetLife Investment Management’s scPharmaceuticals SCPH Stock Holding History

MetLife Investment Management’s Portfolio SCPH Stock Details SCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-22,449	Closed	-$127K	–	2864
2025 Q3	$127K	Buy	22,449 +1,123	+5%	+$5.75K	﹤0.01%	2542
2025 Q2	$81.3K	Buy	+21,326	New	+$66.2K	﹤0.01%	2641
2024 Q4	–	Sell	-16,974	Closed	-$77.4K	–	2851
2024 Q3	$77.4K	Buy	16,974 +9,752	+135%	+$47.2K	﹤0.01%	2702
2024 Q2	$31.4K	Sell	7,222 -8,082	-53%	-$35.5K	﹤0.01%	2843
2024 Q1	$76.8K	Sell	15,304 -19	-0.1%	-$106	﹤0.01%	2647
2023 Q4	$96.1K	Hold	15,323	–	–	﹤0.01%	2624
2023 Q3	$109K	Hold	15,323	–	–	﹤0.01%	2534
2023 Q2	$156K	Buy	+15,323	New	+$160K	﹤0.01%	2413

MetLife Investment Management's SCPH Position: Q4 2025 in Review

MetLife Investment Management sold out of scPharmaceuticals (SCPH) in Q4 2025, closing a stake of 22,449 shares — an estimated $127K sold.

MetLife Investment Management first reported a position in SCPH in Q2 2023 and held it in 8 quarters. The position peaked at $156K in Q2 2023. 0 funds tracked by Wall St. Rank hold SCPH as of Q4 2025.

MetLife Investment Management reported no remaining scPharmaceuticals position as of Q4 2025 after selling out during the quarter.
MetLife Investment Management sold 22,449 scPharmaceuticals shares in Q4 2025, an estimated $127K.
MetLife Investment Management first reported a position in scPharmaceuticals in Q2 2023 and held it in 8 quarters.
MetLife Investment Management's scPharmaceuticals position peaked at $156K in Q2 2023.
0 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2025.

Based on MetLife Investment Management's 13F filing for Q4 2025, filed 12 Feb 2026.